Gilead snags equity stake in Vir with up to $1.87B deal for three T cell engagers

Summary

Gilead Sciences acquires an equity stake in Vir Biotechnology through a deal valued up to $1.87 billion for three T cell engagers, with $135 million in upfront and near-term payments. The partnership represents platform validation for Vir as investors await clinical data in solid tumors.